Table 5 Association of Lp(a) with MACE after excluding patients with eGFR < 30 ml/min/1.73m2.

From: The nonlinear association between lipoprotein(a) and major adverse cardiovascular events in acute coronary syndrome patients with three-vessel disease

 

Model 1

 

Model 2

 

Model 3

 

Model 4

 

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

T1

Ref.

-

Ref.

-

Ref.

-

Ref.

-

T2

1.232 (0.971, 1.564)

0.087

1.151 (0.905, 1.463)

0.251

1.161 (0.912, 1.478)

0.225

1.065 (0.836, 1.357)

0.609

T3

1.829 (1.462, 2.289)

< 0.001

1.679 (1.339, 2.104)

< 0.001

1.650 (1.316, 2.070)

< 0.001

1.339 (1.056, 1.697)

0.016

P for trend

-

< 0.001

-

< 0.001

-

< 0.001

-

0.027

Lp(a)

1.001 (1.001, 1.001)

< 0.001

1.001 (1.001, 1.001)

< 0.001

1.001 (1.001, 1.001)

< 0.001

1.001 (1.000, 1.001)

< 0.001

Log10Lp(a)

1.964 (1.533, 2.516)

< 0.001

1.785 (1.391, 2.292)

< 0.001

1.756 (1.369, 2.253)

< 0.001

1.432 (1.108, 1.852)

0.006

  1. Model 1: unadjusted; Model 2: adjusted for age; Model 3: adjusted for age, hypertension, diabetes, stroke, CKD, antihypertensive drugs, and antidiabetic drugs; Model 4: adjusted for Model 3 + GRACE, Gensini, LVEF, FPG, HbA1c, albumin, uric acid, eGFR, and fibrinogen. Lp(a), lipoprotein(a); MACE, major adverse cardiovascular events; CKD, Chronic kidney disease; LVEF, left ventricular ejection fraction; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; HR, hazard ratio; CI, confidence interval.
Back to article page